HOME >> BIOLOGY >> NEWS
Novel approach to cancer drug given major boost

Scientists at the ProXara Biotechnology Limited have identified a way of switching off one of the key mechanisms that leads to the development and growth of a tumour. Under the Wellcome Trust's Seeding Drug Discovery initiative, the researchers hope to use their findings to develop a drug which could be used to fight cancer. The funding will be used to develop the drug to a point at which it is close to entering a clinical trial.

All cells in the body contain protein kinase B (PKB), a naturally-occurring enzyme that if active prevents cells from committing suicide. Programmed cell death, or apoptosis, is an important process in the body's development, but when this process goes wrong, unregulated cell growth occurs, leading to the development of tumour cells.

Recent research has shown that certain types of genetic damage, common to many cancer cells, lead to the movement of PKB from the interior of the cell to its surface membrane. When PKB attaches to the surface membrane, it becomes active, triggering a signal that tells the cell not to commit suicide. Professor Jeremy Tavar at ProXara Biotechnology Ltd, a spin-out company at the University of Bristol, believes that by preventing PKB binding to the cell's surface membrane, he can ensure that apoptosis occurs, thus killing the cancer cells.

"There has been a lot of interest in targeting PKB as a way of preventing tumour growth," says Professor Tavar. "Most of the interest so far has been in developing drugs that block the enzyme's signal. However, such drugs are very non-specific and can have many adverse side effects. We are working on a novel approach to prevent PKB actually binding to the cell membrane."

Professor Tavar and his team have discovered a drug-like compound, which prevents PKB binding to the cell membrane and makes the tumour cells commit suicide. They now wish to develop this compound to a point at which it could be used in clinical trials.

"Professo
'"/>

Contact: Craig Brierley
c.brierley@wellcome.ac.uk
44-207-611-7329
Wellcome Trust
14-Jan-2007


Page: 1 2

Related biology news :

1. Novel sugar-to-hydrogen technology promises transportation fuel independence
2. Novel system developed to turn data into real-time, interactive 3-D images
3. Novel strategies for healthy aging
4. Novel salamander robot crawls its way up the evolutionary ladder
5. Novel test identifies lymphoma patients likely to respond to new therapy
6. Novel laboratory technique nudges genes into activity
7. Novel approaches to tackling obesity, cancer and MRSA
8. Novel regulation of the common tumor suppressor PTEN
9. Novel EGFR ectodomain mutations in glioblastoma
10. Novel regulatory mechanism identified for key tumor suppressor p53
11. Novel experiment documents evolution of genome in near-real time

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/22/2019)... ... 21, 2019 , ... The inventors of a new and ... major step forward with that therapy, known as SurVaxM. MimiVax LLC principals Robert ... from Roswell Park in 2012, has entered into a China-exclusive licensing agreement for ...
(Date:11/19/2019)... ... November 19, 2019 , ... Project Lifeline – ... Stores (NACDS) Foundation to address substance use disorder (SUD) – will take ... who have led to the program’s effectiveness in preventing and treating opioid abuse in ...
(Date:11/19/2019)... ... , ... The inaugural Cell & Gene Therapy Day takes place February 27, ... will be chaired by Dr Aiman Shalabi, VP R&D, Cell and Gene Therapies for ... witnessing significant innovation in cell and gene therapies, and we are at a turning ...
Breaking Biology News(10 mins):
(Date:11/6/2019)... ... November 06, 2019 , ... LeadingBiotech ,?an exclusive ... announces its East/West CEO conference to be held January 11-12, 2020 ... Kicking off the week of the J.P. Morgan Healthcare Conference and other biotech ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... it has received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy ... user-friendly interface, the Fusion Bx 2.0 will give urologists across Europe the ability ...
(Date:11/2/2019)... TORONTO (PRWEB) , ... October 31, 2019 , ... ... are not always used to communicating with each other: study managers, principal investigators, ... cause misunderstandings if a party is not informed of the latest data, potentially ...
(Date:11/2/2019)... ... October 31, 2019 , ... ... pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical language ... allows researchers to quickly uncover relationships between genes, diseases, variants, phenotypes, and other ...
Breaking Biology Technology:
Cached News: